The effect of sitagliptin and metformin on the quality of oocyte and embryos, the number of retrieved oocyte

Comparison of the effect of sitagliptin and metformin on oocyte and embryo quality, number of retrieved and fertilized oocyte and embryo the Polycystic ovary syndrome (PCOS) insulin-resistant women undergoing In vitro fertilization (IVF)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220803055607N1

Enrollment

Registered

2022-08-04

Start date

2022-08-13

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: Intervention group 1: PCO women treated with sitagliptin (Elixir Pharmaceutical Company) 100 mg three times a day. Intervention 2: Intervention group: PCO women tre

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Diagnosis of Polycystic ovary syndrome (PCOS) based on Rotterdam criteria Age 18 to 40 years BMI=20 Insulin resistant In vitro fertilization (IVF) candidate Not taking drugs that are effective on the activity of two drugs at this time in the last 3 months Not taking weight-loss drugs or having any slimming diet or regular aerobic exercise in the last 3 months Not receiving assisted reproductive treatments in the last 3 months

Exclusion criteria

Exclusion criteria: Getting pregnant during the study The patient's lack of consent to enter or the patient's lack of cooperation in taking the medicine smoking

Design outcomes

Primary

Measure	Time frame
Oocyte and embryo quality. Timepoint: Two months after the start of the intervention. Method of measurement: The average number of retrieved oocyte, fertilized and formed embryos with excellent quality.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSedigheh Esmaeilzadeh

Babol University of Medical Sciences

s.esmaeilzadeh@mubabol.ac.ir+98 11 3233 8301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026